A topic-first view of the current reading queue for clinicians who arrive with a specific area in mind.
Read the full policy before changing a reversal pathway: the feed identifies the clinical question but does not reproduce the recommendation wording, strength or patient-specific exceptions.
Reassess patients on HFNO at 60 minutes and use HACOR as one escalation signal. The established >5 threshold remains the reference; do not adopt the exploratory ≥8 cutoff without prospective validation.
Use it as a team-training and cognitive-aid update for a rare, time-critical procedure; local activation criteria, equipment and role allocation should be rehearsed before the next case.
Do not infer benefit or equivalence from this excerpt alone; review the linked appraisal and primary trial before changing prehospital blood-product protocols.
Services using or considering this device should urgently review the full warning, manufacturer instructions, anatomical risks, governance and training before deployment.
Do not interpret the absence of a dose-response as proof of no treatment effect; read the trial and correspondence together before drawing procedural or dosing conclusions.
This is a useful orientation to the issue, but its PENG-block discussion duplicates the primary trial ranked above; read the original study for methods and limitations.
A favourable physiological surrogate is not enough to support routine manual pressure augmentation during cardiac arrest when patient-centred outcomes have not improved.
When an ECG pause is physiologically inconsistent, inspect all leads and waveform continuity for acquisition artefact before diagnosing true bradyarrhythmia.
Avoid preventable delay when norepinephrine is indicated, but treat the 60-minute threshold as observational evidence rather than proof that earlier treatment itself reduces mortality.
The news summary does not establish a clear bedside winner. Review the primary trial's effect estimates and subgroup findings before revising paediatric sepsis fluid protocols.
PENG block is a promising opioid-sparing option when trained staff are available, but the very small, unblinded trial should not be treated as definitive evidence of superiority or safety.